PubMedCrossRef 22. Fyfe JAM, Harris G, Govan JRW: Revised Pyocin Typing Method for Pseudomonas aeruginosa.
J Clin Microbiol 1984, 20:47–50.PubMed 23. Newman JV, Kolter R, Laux DC, Cohen PS: Role of leuX in Escherichia coli colonization of the streptomycin-treated mouse large intestine. Microb Pathog 1994, 17:301–311.PubMedCrossRef 24. Rang CU, Licht TR, Midtvedt T, Conway PL, Chao L, Krogfelt KA, Cohen PS, Molin S: Estimation of growth rates of Escherichia coli BJ4 in streptomycin-treated and previously germfree mice by in situ rRNA hybridization. Clin Diagn Lab Immunol 1999, 6:434–436.PubMed 25. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, von Wright A: Persistence of colonization selleck chemicals of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 1999, 65:351–354.PubMed 26. Morelli L, Zonenschain D, Callegari ML, Grossi E, Maisano
F, Fusillo M: Assessment of a new synbiotic preparation in healthy volunteers: survival, persistence of probiotic strains and its effect on the indigenous flora. Nutrition journal 2003, 2:11.PubMedCrossRef 27. Saavedra JM: Clinical applications of probiotic agents. Am J Clin Nutr 2001, 73:1147S-1151S.PubMed 28. Saavedra JM, Tschernia A: Human studies with probiotics and prebiotics: clinical implications. Br J Nutr 2002, 87:S241-S246.PubMedCrossRef 29. Sanders ME: Considerations for use of probiotic bacteria to modulate PRT062607 human health. J Nutr 2000, 130:384S-390S.PubMed 30. Senok AC, Ismaeel PtdIns(3,4)P2 AY, Botta GA: Probiotics: facts and myths. Clin Microbiol Infect 2005, 11:958–966.PubMedCrossRef 31. Santosa S, Farnworth E, Jones PJH: Probiotics and their potential health claims. Nutr Rev 2006, 64:265–274.PubMedCrossRef 32. Patzer SI, Baquero MR, Bravo D, Moreno F, Hantke K: The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN. Microbiology 2003, 149:2557–2570.PubMedCrossRef 33.
Michael S: Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1012–1018.CrossRef 34. Smajs D, Strouhal M, Matejkova P, Cejkova D, Cursino L, Chartone-Souza E, Smarda J, selleckchem Nascimento AM: Complete sequence of low-copy-number plasmid MccC7-H22 of probiotic Escherichia coli H22 and the prevalence of mcc genes among human E. coli. Plasmid 2008, 59:1–10.PubMedCrossRef 35. Donnet-Hughes A, Rochat F, Serrant P, Aeschlimann JM, Schiffrin EJ: Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose. J Dairy Sci 1999, 82:863–869.PubMedCrossRef 36. Su P, Henriksson A, Mitchell H: Prebiotics enhance survival and prolong the retention period of specific probiotic inocula in an in vivo murine model. J Appl Microbiol 2007, 103:2392–2400.PubMedCrossRef 37.